Skip to content
Sign in
Venture capitalBacked 1 network startup

KdT Ventures

Physician-founded Austin VC ($250M+ AUM) backing science-driven therapeutics, digital health, industrial biotech and climate companies.

Austin, United States
Ticket
$500K–$5M
Assets under management
$250M
Founded
2017
Stages
Pre-seedto Series A
Network startups backed
1
Co-investors
5most often with Cavallo Ventures

How they invest

Science-driven companies in therapeutics, digital health, industrial biotech and climate; 65+ portfolio companies. Physician and PhD partners suggest deep technical diligence.

Stage and ticket

Pre-seed to Series A; $0.5M–$5M.

Geography

United States.

What makes them say yes

  • Platform science with defensible IP
  • Technical founders (PhD/MD)
  • Industrial biotech or therapeutics with clear first application

Red flags

  • Non-US companies
  • Pure software without science moat

Sectors

  • Biotech & life sciences
  • Deep tech & materials

Stages

  • Pre-seed
  • Seed
  • Series A

Geographies

  • United States

How to approach

Warm intro via ZymoChem (KdT seed and Series A) to Cain McClary, M.D. or Phil Grayeski, Ph.D.

Partners

  • Cain McClary, M.D.Founder and Managing Partner
  • Phil Grayeski, Ph.D.Managing Partner
  • Mack Healy, J.D.Managing Partner
  • Patrick Malone, M.D., Ph.D.Partner

Portfolio

1 network startup · no other company

Follows on (ZymoChem seed → Series A) in industrial biotech.

Gaps in the portfolio

  • Therapeutics
  • Digital health

Network startups

  • ZymoChem2026 World Champion

    Carbon-efficient microbial fermentation platform producing BAYSE, a bio-based superabsorbent designed to replace petroleum SAP in hygiene products.

    United States · Biotech & life sciences

Network startups that fit

5 analysed

Davis biotech using baker’s yeast to deliver RNAi that kills insect pests, starting with cockroaches, without hazardous chemicals.

US seed yeast-based RNAi biopesticides — industrial biotech platform, KdT's ZymoChem playbook.

60%confidence

Evidence from the records

  • “industrial biotech”
  • “Yeast-based RNAi biopesticides”
  • “RNAi biopesticide platform in development (initial target: cockroaches)”
Intro path
Founder-to-founder intro via ZymoChem (network portfolio company of KdT Ventures).
First step
Ask ZymoChem's founders for an intro.

Preclinical biotech licensing University of Miami RNA aptamers to regenerate beta cells in type 1 diabetes and target solid tumours.

US RNA aptamers for type 1 diabetes and solid tumours — therapeutics at pre-seed.

50%confidence

Evidence from the records

  • “therapeutics”
  • “RNA aptamers – type 1 diabetes and solid tumors”
  • “No public evidence of traction found: preclinical RNA aptamer pipeline.”
Intro path
Founder-to-founder intro via ZymoChem (network portfolio company of KdT Ventures).
First step
Send a science summary to the partners.

San Diego maker of fully defined, serum-free stem cell media that lower cost and variability for iPSC research and biomanufacturing.

US serum-free stem-cell media with NIH SBIR Phase II — enabling biotech.

50%confidence

Evidence from the records

  • “"Biotech & life sciences"”
  • “Serum-free culture media for stem cells”
  • “Range of 11 media and reagents on sale, used by laboratories (UC San Diego, Tufts, Penn State, Vala Sciences…).”
Intro path
Founder-to-founder intro via ZymoChem (network portfolio company of KdT Ventures).
First step
Send a non-confidential deck.

Drop-in thermostable microbial additive that makes compostable plastics fully degrade, sold to processors facing rising EPR fees.

US microbial biodegradable-plastic additives — industrial biotech + climate.

45%confidence

Evidence from the records

  • “climate”
  • “Biodegradable plastics / microbial additives”
  • “Additive at TRL 5 in commercial-scale pilot tests with partner plastics processors (not named)”
Intro path
Founder-to-founder intro via ZymoChem (network portfolio company of KdT Ventures).
First step
Ask ZymoChem for an intro.

Tufts spin-off with an IRB-approved ingestible capsule that samples small-intestine microbiome and contents non-invasively.

US ingestible gut-sampling capsule — digital health/diagnostics.

35%confidence

Evidence from the records

  • “digital health”
  • “Ingestible small intestine sampling capsule”
  • “Capsule validated in 3 large animal models and NSR/IRB approved for human use”
Intro path
Founder-to-founder intro via ZymoChem (network portfolio company of KdT Ventures).
First step
Send NIH-grant data.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Co-investors

Most often with Cavallo Ventures, GS Futures, and Breakout Ventures

Sources